GlassScriptPhysician profile
Scott M Dale
NPI 1760408785
$5,001.03
in general payments reported to CMS, 2019-2025
30 companies · $886 in 2025
The $886 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $164 · 2021: $481 · 2022: $787 · 2023: $757 · 2024: $941 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,024.66 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $456.83 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $422.55 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $358.04 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $305.75 | 2019-2024 | Duobrii, Siliq |
| Pfizer INC. | $302.54 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $259.41 | 2023-2025 | Zoryve |
| Genzyme Corporation | $228.09 | 2021-2025 | |
| Janssen Biotech, INC. | $223.86 | 2020-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $198.67 | 2019-2025 | |
| Amgen INC. | $187.89 | 2021-2025 | Otezla, Otezla, Enbrel |
| Incyte Corporation | $179.65 | 2022-2024 | Opzelura |
| Ucb, INC. | $143.25 | 2022-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $99.87 | 2022-2025 | Adbry |
| Lilly USA, LLC | $91.40 | 2019-2023 | Taltz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $78.93 | 2025 | Nemluvio |
| Organon LLC | $67.73 | 2024-2025 | Vtama |
| Mimedx Group, INC. | $45.96 | 2024-2025 | |
| Dermira, INC. | $39.17 | 2019 | |
| Prugen, INC. Pharmaceuticals | $38.92 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.93 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.14 | 2022-2023 | Sotyktu |
| Helsinn Therapeutics (U.S.), INC. | $31.35 | 2023-2025 | Valchlor |
| Epi Health, LLC | $23.95 | 2019 | |
| Kyowa Kirin, INC. | $22.82 | 2022 | |
| Surgenex LLC | $22.73 | 2025 | Renograft, Surgraft, Ardeograft |
| Merz North America, INC. | $21.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.54 | 2023 | Cyltezo |
| Genentech USA, INC. | $18.76 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Dale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.